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ABSTRACT
The Ewings Sarcoma Oncoprotein (EWS) interacts
withseveralcomponentsofthemammaliantranscrip-
tional and pre-mRNA splicing machinery and is also
found in the cytoplasm and even on the cell surface.
The apparently diverse cellular functions of EWS
are, however, not well characterized. EWS harbours
a potent N-terminal transcriptional activation domain
(the EAD) that is revealed in the context of onco-
genic EWS-fusion proteins (EFPs) and a C-terminal
RNA-binding domain (RBD) that recruits pre-mRNA
splicing factors and may couple transcription and
splicing. In contrast to EFPs, the presumed trans-
criptional role of normal EWS remains enigmatic.
Here, we report that multiple RGG-boxes within the
RBD are necessary and sufficient for cis-repression
of the EAD and that RGG-boxes can also repress
in-trans,withindimericpartners.Lyscanfunctionally
substitute for Arg, indicating that the basic nature of
the Arg side chain is the critical determinant of RGG-
box-mediated repression. In addition to the EAD,
RGG-boxes can repress a broad range of activation
domains (including those of VP16, E1a and CREB),
but repression can be alleviated by the simultaneous
presence of more than one activation domain. We
therefore propose that a key function of RGG boxes
within native EWS is to restrict promiscuous activa-
tion by the EAD while still allowing EWS to enter
functional transcription complexes and participate
in other transactions involving pre-mRNAs.
INTRODUCTION
Much of what is known about the normal function of the
Ewings Sarcoma oncogene (EWS) is derived from studies
of oncogenic fusion proteins (EWS-Fusion-Proteins, EFPs).
EFPs cause a variety of malignancies [reviewed in (1–3)]
and arise from chromosomal fusion of the EWS gene with
multiple partners. Our previous work has focused on EWS/
ATF1 (Figure 1), an EFP which is a causative agent of soft
tissue clear cell sarcoma (CCS) (4). EFPs are potent promoter-
speciﬁc transcriptional activators, due to the presence of the
N-terminal region of EWS (the EWS-Activation-Domain,
EAD) and a DNA binding domain from the fusion partner.
In addition to inﬂuencing transcriptional events in tumour
cells, EFPs also perturb pre-mRNA splicing, suggesting that
the mechanisms of tumorigenesis may be quite complex.
The cellular role of the normal EWS protein is not well
characterized. In addition to the EAD, EWS contains a
C-terminalRNA-bindingdomain(RBD,Figure1)andtogether
with the highly related proteins TLS/FUS and TAF68, forms a
sub-group [the TET family (5)] within the RNP family of
RNA-binding proteins (6–8). The presence of the RBD points
to a role for TETs in aspects of RNA biogenesis other than
transcription and there is muchevidence that TETs are directly
involved in pre-mRNA splicing and transport or in coupling
of the splicing and transcriptional machinery (9–13). Finally,
TETs are targets for tyrosine kinases (14,15) and possibly
othersignalling pathways (16,17), and are also found toshuttle
between several cellular locations (14,18,19) including the
cell surface (19). Thus, it is apparent that TETs participate
in a diverse array of cellular functions.
Similar to splicing, there is a signiﬁcant body of evidence to
implicate EWS/TETs in transcription. First, as mentioned
above, the EAD functions as a potent transcriptional activation
domainin the context ofEFPs (1,3) and particularly in the case
of EWS/ATF1 (20–22). Second, native EWS/TETs interacts
with a gamut of transcription factors, including Pol II subunits
(23,24), activators (25–27) and co-activators (28,29), and the
TET ﬂy homologue, SARFH, associates with many Pol II
transcription units in vivo (30). Different TETs (including
EWS) are present in distinct TFIID sub-populations however
(5), indicating that, despite making contact with multiple tran-
scriptional components, TETs are not general transcription
factors. Third, native EWS (28,29) and TLS (27) can modestly
stimulate transcription in a cell or promoter-speciﬁc manner
*To whom correspondence should be addressed. Tel: +852 2358 8636; Fax: +852 2358 1559; Email: bokaw@usthk.ust.hk
ª The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 4 1323–1331
doi:10.1093/nar/gki270(27–29) further pointing to a specialized transcriptional role of
TETs. The ﬁnding that a cis-linked EWS RBD can block
trans-activation by the EAD in the context of EFPs (31) or
Gal4-fusions(28,31,32)indicatesthattheRBDcanprofoundly
inﬂuence the transcriptional properties of EWS. The RBD
contains features common to several other RNA-binding
proteins [(6–8) and see Figure 1] although the natural RNA
ligands are not yet known. The RBD binds to synthetic
ribopolymers and to ssDNA (33,34) and the recent demonstra-
tion of sequence-speciﬁc RNA binding by TLS (35) may point
to a more speciﬁc regulatory role. Signiﬁcantly, the isolated
RGG3 region of EWS [(33), Figure 1] and the homologous
RGG rich regions of TLS (34,35) and hnRNPU protein (36)
are sufﬁcient for the interactions with RNA mentioned above.
Besides a role in RNA binding, RGG-boxes are also able
to mediate protein–protein interactions (7,8) and particular
RGG-box interacting proteins include splicing components,
namely the SR family of splicing factors (37) and the multi-
functional SMN protein (38). Finally, the RGG-boxes of
G3BP and nucleolin are implicated in RNA/DNA helicase
activity (39) and RGG-boxes in hnRNPK (40) and hnRNPD
and nucleolin (41) are required for transcriptional activation.
Together, the above ﬁndings suggest that RGG-boxes, like
TETs, may perform several functions.
Here, we demonstrate that RGG-boxes within the EWS
RBD are necessary and sufﬁcient for repression of several
transcriptional activation domains, including the EAD. We
also describe additional features of RGG-box mediated
repression which point to a signiﬁcant role for RGG boxes
in determining the transcriptional properties of native EWS.
MATERIALS AND METHODS
Plasmids and constructions
The reporters pD( 71)SomCAT (42), pG1E4TCAT,
pG5E4TCAT, pZ7E4TCAT (43) and pBS2CAT (44) are as
previously described. The protein expression vectors
pSVEWS/ATF1 (20), pD87C (45), p87R, pNC and pG4NC
(31), pBSAPCREB (44) and pbZ3EA/pbZ12EA (45) are as
described previously. pRGG contains EAD residues 1–86
fused to the RGG3 region of EWS (residues 545–656) and
was obtained by insertion of a BglII/XhoI fragment from
pRM2 (31) into BglII and XhoI digested p87R. pLR1 was
obtained by inserting a BglII/EcoRI ended PCR product con-
taining EWS residues 571–604 (from RGG3) into BglII/EcoRI
digested pRGG. To construct pLR2 and pLR4, a BglII/XbaI
fragment from pLR1 or pLR2 respectively, was inserted into
BamHI/XbaI digested pLR1 or pLR2. pSR1 was obtained by
inserting oligonucleotides encoding EWS residues 587–604
(from RGG3) into BglII/EcoRI digested pRGG. pSR2 and
pSR4 were constructed by cloning a BglII/XbaI fragment
from pSR1 or pSR2 into BamHI/XbaI digested pSR1 or
pSR2. pSRm1, pSRm2, pSRm3 and pSRm4 were constructed
in the same manner as pSR4, using oligonucleotides contain-
ing the desired mutations. All inserts were sequenced to ensure
the absence of extraneous mutations. pEASR4 and pEASRm1
were obtained by inserting a HindIII/BglII fragment from pNC
into HindIII/BglII digested pSR4 and pSRm1 respectively.
pBCREBvec was obtained by inserting an oligonucleotide
containing the desired restriction sites into XbaI digested
pBSAPCREB. pBCREBR was obtained by inserting an XbaI
fragment from pG4NC into NheI/XbaI digested pBCREBvec.
pG4E1a and pG4VP16 were obtained by inserting SalI/BglII
ended PCR products containing the activation domains of E1a
(residues 121–223) and VP16 (residues 413–490), into SalI/
BglII digested pG4NC. pE1aR and pVP16R were obtained by
insertion of a BglII/XbaI fragment from pG4NC into BglII/
XbaIdigested pG4E1aandpG4VP16, respectively. pVPSRm2
and pVPSR4 were obtained by inserting a BglII/BamHI frag-
ment from pSRm2 and pSR4 respectively into BglII digested
pG4VP16. pVPvec was obtained by cloning an oligo-
nucleotide containing an in-frame EcoRI site, into pVP16R
digested with BglII and XbaI. pVPNC was obtained by insert-
ing in a EcoRI fragment from pVPvec into EcoRI digested
pG4NC. pVPE was obtained by digestion of pVPNC with
XbaI and religation to remove the RBD. VPESRm2 and
pVPESR4 were obtained by inserting a BglII/XbaI fragment
from pVPSRm2 and pVPSR4 into BglII/XbaI digested
pVPNC. pbZ3 and pbZ12 were obtained by inserting oligonu-
cleotides containing a functional initiation codon into BglII/
NdeI digested pbZ3EA and pbZ12EA. pbZ3LR4 (or pbZ12-
LR4), pbZ3SR4 (or pbZ12SR4) and pbZ3SRm1 (or pbZ12-
SRm1) were obtained by inserting the BglII/BamHI fragment
from pLR4, pSR4 and pSRm1 into pbZ3EA or pbZ12EA
digested with BglII. pbZ3RBD was obtained by inserting a
BglII/NdeI fragment from pNC into BglII/NdeI digested
pbZ3EA, followed by removal of the ATF1 N-terminal
sequence by digestion with BglII and NdeI, and insertion of
an oligonucleotide to maintain the reading frame.pbZ3VPSR4
was obtained by inserting a blunt-ended PCR fragment con-
taining the VP16 activation domain into BglII digested blunt-
ended pbZ3SR4.
Figure1. FunctionalregionsofEWS,ATF1andEWS/ATF1.EWScontainsan
N-terminal transcriptional activation domain (the EWS-Activation Domain,
EAD) and a C-terminal RNA-binding domain (RBD). The RBD contains
two elements [anRNA-RecognitionMotif (RRM)andRGG boxes] commonly
foundinRNAbindingproteins(6–8)andaC2–C2putativezincfinger(Z).The
RRM (otherwise called the CS-RBD or the RNP motif) consists of  100
residues with a conserved three dimensional structure (6–8). The three RGG
rich regions (RGG1, RGG2 and RGG3) contain 5, 3 and 12 tripeptide RGG
motifs, respectively. The term RGG-box refers to clusters of closely spaced
RGG tripeptidesflankedby aromatic residues anda consensusRGG-box(con-
taining 5 RGG tri-peptides) has been deduced (8). ATF1 is a PKA-inducible
activator (47,48). The bZIP domain of ATF1 (amino acids 214–271) mediates
dimerization and DNA-binding, Q2 is a glutamine-rich constitutive activation
domain(48)andPKArepresentstheKinaseInducibleDomain(48)includinga
single PKA-phosphoacceptor site. EWS/ATF1 is an oncogenic EWS-Fusion-
Protein (EFP) that is associated with soft tissue clear cell sarcoma (CCS) (4).
The chromosomal cross-over point that produces EWS/ATF1 is shown with a
blackcrossresultingintheEAD(residues1–325)fusedtotheC-terminalregion
of ATF1 (residues 66–271). EWS/ATF1 lacks the PKA phosphoacceptor site
of ATF1 and functions as a potent constitutive activator of ATF-dependent
promoters (20,21) dependent on the EAD and the bZIP domain of ATF1.
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JEG3 cells were grown in DMEM containing 10% FCS.
Transfections, CAT assays and western blotting of epitope-
tagged proteins using monoclonal antibody KT3 (46) were
carried out as previously described (31). For quantitation,
percentage conversion of unacetylated to acetylated
14C-chloramphenicol under linear assay conditions was
determined by excision of spots from the TLC plate and quant-
itation of radioactivity using a liquid scintillation counter.
RESULTS
A repression assay for small regions of the EWS RBD
Our previous studies of EFPs and RBD-mediated repression
of the EAD have focused on EWS/ATF1 (Figure 1), the EFP
which causes soft tissue clear cell sarcoma (4). Unlike ATF1
which is a cAMP-inducible activator (47,48), EWS/ATF1 is
a potent constitutive activator of ATF-dependent promoters
(20,21), dependent on multiple elements dispersed throughout
the EAD (45) including a consensus SYGQQS repeat with a
critical Tyr residue (22). Our previous ﬁndings (31) suggested
that RGG-boxes within the EWS RNA-binding domain (RBD,
Figure 1) and the RGG tripeptides therein, might be necessary
for cis-repression of the EAD. Testing this hypothesis is hin-
dered by the number of RGG tripeptides (a total of 20) in the
RBD which renders mutational analysis technically difﬁcult.
Realistically, the above task can only be achieved via total
synthesis of mutated oligonucleotides and reiterative sub-
cloning. This in turn requires establishment of a functional
repression assay for smaller regions of the RBD (in practice,
 40 residues or 120 nt). In light of the contribution of the
RGG3 region to repression (31) and due to the high density of
RGG tripeptides within RGG3, we attempted to exploit the
RGG3 region to achieve the above objective.
Despite the signiﬁcant effect of deleting RGG3 on repres-
sion of the intact EAD (31) RGG3 alone only moderately
represses the EAD, perhaps due to the magnitude of activation
by the EAD. To establish a more workable assay for RGG3-
mediated repression (Figure 2), we tested the ability of RGG3
Figure 2. An assay for repression by small regions of the EWS RBD. (A) Structure of experimental proteins. For reference, the structure of EWS, ATF1 and
EWS/ATF1 are described in Figure 1. D87C (45) is a derivative of the EWS/ATF1 oncogenecontaining only the N-terminal 86 residues of the EAD fused to ATF1
(residues 66–271) including the bZIP domain that allows dimerization and DNA binding. D87C is a constitutive activator of ATF-dependent promoters dependent
on the EAD region(45). RGG3 corresponds to residues 545–656of intact EWS. All of the novel proteins testedare derivedfrom D87C by insertion ofthe indicated
sequence between the EAD and ATF1 regions. The ATF1 region is thus present in all proteins but is not shown in the diagram. The amino acid sequence of a short
repeat(SR,lightgreenbox)andalongrepeat(LR,darkgreenbox)arepresentwithintheRGG3regionofEWS(LRcontainsEWSresidues571–604andSRcontains
EWSresidues587–604).ThenumberofRGG-tripeptidesineachproteinandtherelativetranscriptionactivityareshowntotheright.(B)Transcriptionassays.JEG3
cells were transfected with 5 mg of ATF-dependent reporter [pD (71)SomCat] and 5 mg of plasmid expressing the activator indicated. Transcriptional activity was
monitored by CAT assay and a representative TLC result is shown at the bottom (c = chloramphenicol; and ac = acetylated chloramphenicol). The corresponding
western blot, using monoclonal antibody KT3 (45) to monitor epitope-tagged activator levels, is shown above the CAT assay.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1325torepressthelowerlevelsoftrans-activationbytheN-terminal
region of the EAD (present in D87C) using a previously
described transient assay (31,45). Brieﬂy, an expression vector
for the test protein and an ATF-dependent reporter [pD( 71)
SomCAT] were introduced into JEG3 cells and trans-
activation monitored by CAT assay. As previously shown
(31), the RBD strongly represses D87C (50-fold repression,
compare D87C and 87R, Figure 2B) and RGG3 alone is indeed
able to repress reasonably well (12-fold repression, compare
D87C and RGG).
We next created a series of synthetic proteins (Figure 2A)
containing one (LR1), two (LR2) or four (LR4) copies of a
long repeat (LR, EWS residues 571–605, including seven
RGG tripeptides), or two (SR2) or four (SR4) copies of a
shorter repeat (SR, EWS residues 587–605, including four
RGG tripeptides) present with RGG3. All the above proteins
are expressed at comparable levels in transfected cells
(Figure 2B). While the presence of seven (LR1, 1.7-fold) or
eight RGG tripeptides (SR2, 3-fold) results in very modest
repression, 14 (LR2, 12-fold) or 16 RGG tripeptides (SR4,
17-fold) gave strong repression and 28 RGG tripeptides
(LR4, 32-fold) repress more or less as efﬁciently as the intact
RBD(Figure2B).Overall,theaboveexperimentsrevealaclear
inverse correlation between trans-activation and the number
of RGG tripeptides present, suggesting that RGG tripeptides
are necessary for repression. Furthermore, given that RGG
tripeptides account for  70% of the residues present in LR
and SR,itseems probable thattheyare sufﬁcientforrepression
(see below). Although the above analysis is not extensive, the
results also indicate quite clearly that RGG tripeptides act
synergistically above a certain threshold. For example, 7
RGG tripeptides (LR1) give very a modest effect ( 2-fold
repression ) while 14 (LR2) give much more than an additive
effect (12-fold repression).
Mutational analysis of SR4
The assay described above enabled creation and testing of
mutantstopreciselydeﬁnetheresidueswithinSR4thatmediate
repression (Figure 3). Simultaneous substitution of Arg by Ala
in all four RGG tripeptides present (SRm1) eliminated repres-
sion and even resulted in modest stimulation (2-fold), thus
providing direct evidence that the Arg residues within RGG
tripeptides are required for repression. We note that while
SRm1andinadditionSRm2(ArgtoLys)proteinsareexpressed
at lower levels relative to other mutants tested, the high tran-
scriptional activity of SRm1 demonstrates that this level of
expression is quite sufﬁcient to reﬂect activity. Thus, Lys is
able to substitute for Arg (SRm2) indicating that the basic
nature of the Arg side chain is the important repression deter-
minant. The RGG tripeptides in SR4 are ﬂanked by Phe resi-
dues which are a conserved feature of RGG-boxes in other
RNA-binding proteins (8,49). However, substitution of the
Phe residues in SR4 by Ala (SRm3) had no obvious effect
on the magnitude of repression. Similarly, substitution of the
two remaining residues (Met and Asp) present in SR4 by Gly
(SRm4) had no effect on repression. Because Gly residues
constitute 50% of SR and even substitution by Ala would dra-
matically alter the structure of SR, we did not test the effect of
substituting Gly residues. Together, the above results demon-
strate that the RGG tripeptides within SR4 are necessary and
sufﬁcient for repression, with Arg residues playing a crucial
role.
Fusion of the synthetic RGG-containing elements present
in SR4 and SRm1 to the intact EAD (EASR4 and EASRm1,
Figure 4A) also resulted in effective repression in the case of
EASR4 (10-fold) but not in the case of EASRm1 (2-fold).
Thus, the RGG tripeptides present within SR4 can repress
the intact EAD (see also Figure 5) although less efﬁciently
than can the intact RBD.
Figure 3. Mutational analysis of SR4. Residues present in each mutant are aligned with the SR4 amino acid sequence. RGG tri-peptides are highlighted by green
boxes and point mutations are in red. The relative transcription activity for each mutant (compared with D87C set at 100) is indicated to the right. For experiments,
JEG3cellsweretransfectedwith5mgofATF-dependentreporter[pD (71)SomCat]and5mgofplasmidexpressingtheindicatedactivator.Transcriptionalactivity
was monitored by CAT assay. Middle panel. western blot analysis of KT3 epitope-tagged proteins in transfected cells. Lower panel: representative TLC of CAT
assay (c = chloramphenicol; and ac = acetylated chloramphenicol).
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the RGG-box
To assess repression speciﬁcity, we examined the effect of the
RBD on multiple distinct activation domains (Figure 4A).
G4E1a and G4VP16 contain the Gal4 DNA-binding domain
linked to the adenovirus E1a and VP16 activation domains
respectively and BCREB contains the BSAP DNA-binding
domain linked to the glutamine-rich activation domains
of CREB (44). E1aR, VP16R and BCREBR are the corres-
ponding proteins containing the EWS RBD. Following
co-transfection of JEG3 cells using the appropriate reporter
constructs (see legend, Figure 4A) each of the above activation
domains was strongly repressed by the RBD, although the
magnitude of repression did vary (E1a, 12.6-fold repression;
VP16, 54-fold; BCREB,125-fold). We also tested the capacity
of the synthetic element in SR4 to repress VP16 (Figure 4B)
and found that the magnitude of repression of VP16 in this
case (73-fold, compare G4VP16 with VPSR4 ) is comparable
with that achieved by the intact RBD (54-fold).
The above experiments do not indicate whether repression
by the RGG boxes is direct or indirect. To address this issue,
weasked whetherthesyntheticelementinSR4orthe RBDcan
simultaneously repress two distinct activation domains (VP16
and the EAD) present in the same molecule (Figure 4B). In
the experiment shown, the RBD strongly represses the EAD
(18-fold) and VP16 (39-fold) activation domains when the
latter are present alone but when the EAD and VP16 are
together (VPNC) potent transcriptional activation is restored
(compare VPNC with VP16R or G4NC). Quantitation (in the
linear range of the CAT assay) reveals that activation by
Figure4. SpecificityanddominanceofRGG-boxmediatedrepression.(A)EffectoftheRBDonsingleactivationdomains(EAD,VP16,E1aandCREB).(B)Effect
of RBD on two activation domains (EAD and VP16) present together. JEG3 cells were transfected with plasmids expressing the proteins indicated (as described in
MaterialsandMethods)togetherwiththefollowingreporterconstructs:p(D 71)SomCat(foractivatorscontainingtheATF1DNA-bindingdomain);pBS2CAT(for
activators containing the BSAP DNA-binding domain); pG5E4TCAT (for G4E1a and E1aR) and pG1E4TCAT (for VP16 and derivatives). CAT assays were
performed 40 h post-transfection and a representative CATassay is shown. Relativetranscriptionactivity is shownin parenthesis to the right of each protein tested.
Forsingleactivationdomains(A)activityintheabsenceoftheRBDissetat100.ForthejointactivityofVP16andtheEAD(B)theactivityofG4VP16issetat100.
Figure 5. Effect of the RBD in obligatory heterodimers. JEG3 cells were
transfected with a Zta reporter plasmid (pZ7E4TCAT) together with two
other plasmids expressing either a bZ12 derivative (as indicated to the left)
orbZ3derivative(indicatedtotheright).Thus,theresultantdimericproteinsin
eachcasewillconsistofaheterodimercontainingonebZ12partnerandonebZ3
partner.CATassayswereperformed40hpost-transfectionandarepresentative
CAT assay is shown. Relative transcription activity for each heterodimer is
shown in the right hand column with the bZ3EA/bZ12EA combination set at
100. nd, not determined.
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(60-fold) and the EAD (22-fold) alone. Thus, even when the
RBD is present (VPNC) VP16 and the EAD together give very
potent synergistic activation, indicating that two activation
domains can work together to counteract RGG-mediated
repression. Deletion of the RBD from VPNC results in only
a modest increase in trans-activation (3-fold, compare VPNC
and VPE) conﬁrming that repression is indeed largely over-
come by the joint action of VP16 and the EAD. Similar to
the effect of the RBD, while the EAD and VP16 alone are
repressed by either SR4 or SR4m2 (Figure 4B), activation is
restored in both cases when the EAD and VP16 are present
together (compare VPESR4 with VPSR4 and VPESRm2 with
VPSRm2). The above results demonstrate that RGG-boxes
(or the RBD) do not prevent entry of cis-linked activation
domains (the EAD and VP16) into functional transcription
complexes. In addition, while all activation domains tested
can be repressed, repression is not dominant but can (at
least in the case of VP16 and the EAD) be counteracted by
the presence of an additional activation domain.
Trans-repression by the RGG-box within
heterodimeric complexes
While the RBD does not repress the EAD in trans (i.e. when
not recruited to the promoter) (data not shown), we wanted to
determine whether the RBD (or SR4) could repress the EAD
when present in heterodimeric complexes. To achieve this, we
exploited obligatory dimerization partners (Figure 5) and a Zta
DNA-binding domain to avoid interference from endogenous
ATF1/CREB as previously described (45,47). bZIP domain
proteins bZ3 and bZ12 contain the Zta basic domain (b) and
mutated ATF1/CREB leucine zippers (Z3 and Z12) that do
not homodimerize but do form heterodimers (47,50). Thus,
bZ3 and bZ12 do not homodimerize or bind to Zta binding
sites, while bZ3/bZ12 heterodimers form efﬁciently and can
therefore be exploited to produce and assay any desired
heterodimer.
As expected (Figure 5), a combination of bZ3 and bZ12
gave little trans-activation of a reporter (pZ7E4TCAT) con-
taining Zta binding sites, while a bZ3EA/bZ12EA heterodimer
(essentially representing homodimeric EWS/ATF1 with each
partner containing the intact EAD and ATF1) strongly activ-
ates (set at 100%) as previously shown (45). We analysed a
series of heterodimers obtained by combining bZ12EA with
various derivatives of bZ3. bZ3 alone combines with bZ12EA
to give signiﬁcant activation (45% of bZ3EA/bZ12EA), indic-
ating that the presence of the EAD in only one partner of a
dimer is sufﬁcient for relatively high levels of activation on a
multi-site reporter (pZ7E4TCAT). bZ3RBD (containing the
intact RBD, 0.9%), bZ3LR4 (containing the LR4 synthetic
element, 2.1%) and bZ3SR4 (containing the SR4 synthetic
element, 3%) all failed to signiﬁcantly activate bZ12EA.
This lack of activation strongly suggested that the RBD and
SR4 are able to repress the EAD within heterodimeric com-
plexes. To substantiate this conclusion, bZ3SR4m1 (contain-
ing Arg to Ala substitutions within SR4) and bZ3VPSR4
(containing the VP16 activation domain in addition to SR4)
were both able to strongly activate in combination with
bZ12EA. A combination of bZ3SRm1 and bZ12SRm1 is
inactive, thus ruling out the possibility that these proteins
activate by themselves. Identical results were obtained, in
each case, in complementary experiments using a combination
of bZ3EA and all of the derivatives described above in a bZ12
background (data not shown). To summarize, there is a
correlation between the ability to repress the EAD in-cis
and the inability to support activation by the EAD in-trans,
and we therefore conclude that the EWS RBD or RGG-boxes,
directly repress the EAD in heterodimeric complexes.
DISCUSSION
Structural requirements for RGG-box-mediated
repression
We have shown that the RGG-box present within the RBD of a
TET family member (EWS) can repress transcriptional activa-
tion by the EAD and a range of other activation domains. The
arginine residues present within multiple RGG tripeptide
motifs are necessary for repression and our data indicate that
the minimal repression element is a reiterated RGG tripeptide
of approximately 12 copies (Figure 2). Lys can functionally
substitute for Arg, indicating that the previously demonstrated
Argmethylation of RGG-boxes within EWS (19) is not critical
for repression. This is similar to the requirement for nucleolar
localization of nucleolin (51) and indicates that the basic
nature of the Arg side chain is the primary repression deter-
minant of RGG-boxes. There is little conservation of spacing
for the intact RGG3 region compared with the synthetic ele-
ments LR2 and SR4, all of which have a similar number of
RGG tripeptides and repress to similar degrees. Thus our
results indicate that the spatial arrangement of RGG tripep-
tides is not highly constrained. RGG-boxes form a ﬂexible
b-spiral structure (7,8) but beyond that, a high resolution
structure/function relationship for the RGG-box (in relation
to transcriptional repression, RNA binding or other functions)
has yet to be determined and represents an important task for
the future.
Mechanism of repression by the RGG-box
Our ﬁnding that repression can be effectively counteracted
by the synergistic action of two transcriptional activation
domains, indicates that the RGG-box does not act indirectly,
e.g., via inhibition of nuclear export of nascent transcripts.
In addition, the likely presence of native EWS in a high
proportion of cellular transcription complexes (5,24) is also
incompatible with a generally repressive effect of the RBD on
events distal to transcription. We therefore interpret our results
to indicate that the individual activation domains tested are
directly repressed by the RGG-box/RGG-tripeptides.
We have previously suggested (31) that repression by the
EWS RBD might be quite selective for the EAD and result
from the RBD blocking interaction between the EAD and the
Pol II subunit RPB7 (23,52). However, the ﬁndings reported
here show that a range of distinct activation domains are
susceptible to repression. A priori, the ability of two activation
domains to alleviate repression, might most readily be
explained by direct physical, and hence competing, interac-
tions between the activation domains and the RBD. However,
the unrelated primary structure of the activators in question
(EAD, E1a, VP16 and the Q-rich activation domains of
CREB) does not support the above possibility. A more likely
1328 Nucleic Acids Research, 2005, Vol. 33, No. 4explanation is that a net increase in activation domains results
in strong synergy and thus a switch from repression to activa-
tion. Striking synergistic effects (more than an order of mag-
nitude) are indeed observed upon a minimal increase in the
number of activation domains in other systems (43,44,53,54).
Thus, we suggest that repression (by the RBD/RGG-boxes)
and activation (by the EAD/VP16) may target different steps
in transcription complex assembly and that the joint positive
effect of the EAD and VP16 overrides the negative effect of
the RBD. Such ‘kinetic synergism’ has been proposed previ-
ously for the multi-step process of transcription complex
assembly (55).
The RGG-box within the RGG3 region of EWS (33), TLS
(34) and the Fmrp protein (56), is sufﬁcient for synthetic
ribopolymer binding. In addition, TLS (and the RGG2/3
region therein) is able to recognize GGUG containing RNAs
of synthetic origin (35). This raises the possibility that
RGG-boxes might mediate repression through their intrinsic
RNA-binding function. In light of the susceptibility of several
different promoters to repression (Figure 4A), we suggest that
sequence-speciﬁc binding of RGG-boxes to nascent mRNA
transcripts is unlikely to be involved in repression. An altern-
ative possibility is that RGG-boxes might interact with a
putative RNA-component of the transcriptional machinery,
precedent for which comes from identiﬁcation of an RNA
that participates in estrogen inducible transcription (58,59).
Ithasbeen proposedthat RGG-boxesbindtoRNA ina manner
similar to the HIV TAT protein (7) in which case an Arg
residue is critical for binding to the HIV TAR element and
Lys cannot substitute for Arg (57). In the above eventuality,
the ability of Lys to allow transcriptional repression by RGG-
boxes would again suggest that RNA-binding by EWS is not
involved in repression.
The RGG-boxes of TETs bind to SR family of splicing
factors (37) and the multifunctional Survival of Motor Neuron
(SMN) protein (38) that may be involved in coupling of tran-
scription and splicing. Binding of EWS to SMN is reduced by
Arg to Lys mutations in the RGG-boxes however (38), indic-
ating that SMN is not likely to be involved in repression.
Another potential feature of repression is suggested by
the DNA/RNA helicase and ATPase activity residing within
the RGG boxes of G3BP and nucleolin (39). Future progress
in uncovering the molecular mechanism of repression will
require biochemical analysis and may also arise from identi-
ﬁcation of novel RGG-box interacting proteins and the physio-
logical RNA ligands for EWS.
Function of EWS
The ability of the isolated RBD to repress transcription by an
array of activation domains raises the possibility that native
EWS could act as repressor. The existence of several other
RNA-binding proteins that repress transcription, including
Nrd1 (60), hnRNP-U (61) and NELF-E (62), ssDBF (63),
SPEN proteins (64), TDP-43 (65) and Sam68 (66), provides
ample precedent for this. In the event that EWS is a repressor,
the involvement of RGG boxes in repression wouldrepresent a
novel mode of action for vis a vis the other repressors men-
tioned above. However, based on the ﬁnding that the EWS
RBD does not act as a dominant repressor, we suggest that
native EWS is unlikely to act as a general repressor within
mammalian transcription complexes that, commonly, contain
multiple synergistic activators.
The ﬁnding that the EAD is such a potent activation domain
inthecontextofEFPsandyetiseffectivelyrepressed(50-fold)
by the RBD, suggests that EAD function within EWS may
be quite distinct to that uncovered in the context of EFPs.
Consistent with this suggestion, the EAD and intact EWS can
have apparently opposite transcriptional effects (28,29,67).
Binding of the EAD (in EWS/ATF1) to the co-activator
CBP represses p53-mediated trans-activation (67) while in
contrast, binding of intact EWS to CBP allows transcriptional
activation (28,29). It is also of signiﬁcance that trans-
activation by EWS (28,29) and TLS (27) is very modest
compared with the EAD and in one case the N-terminal
246 residues of EWS (including most of the EAD) is dispens-
able for activation by EWS (28). The latter observation indic-
atesthattrans-activatonbyEWSdoesnotreﬂectresidualEAD
activity but instead reveals a novel activation capacity of the
EWS RBD. Finally, whatever the transcriptional role of EWS
might be, the EAD presumably plays a positive role in one or
more of the wide range of potential EWS functions alluded to
in the introduction (9–19).
Given the presence of EWS in a wide range of transcription
complexes and the fact that a single, promoter-bound EFP can
activate transcription with such potency (20), it is apparent
that promiscuous activation by the EAD, and hence gross
de-regulation of cellular transcription, must somehow be aver-
ted. Repression of the EAD by RGG-boxes provides a mech-
anism toachievethis.Thus,wesuggestthatonefunctionofthe
EWS RBD is to serve as a negative control element for the
EAD, while still allowing other activators present in particular
transcription complexes to activate. This idea is strongly sup-
ported by the ﬁnding that additional activation domains can
overcome repression by the RBD (Figures 4 and 5). If EWS is,
in many cases, neutral for transcription, then the presence of
EWS in most transcription complexes may reﬂect a role in
coupling of transcription to other RNA transactions in the cell.
The abundant evidence that EWS functionally interacts with
several splicing factors (9–13) supports this idea.
Repression and oncogenesis
The work of several groups (2) has indicated that EFPs are
involved in tumour maintenance, raising the possibility that
EFP/EAD inhibitors might serve as therapeutic leads. Indeed
this objective stimulated the study reported here. The ﬁnding
that RGG-boxes can repress a broad range of activation
domains, however, argues that RGG-boxes will have limited
potential as speciﬁc EAD inhibitors. In contrast, the ability of
RGG-boxes to strongly repress the EAD in heterodimeric
complexes (Figure 5) predicts that RGG-boxes fused to the
ATF1 bZIP domain should function as highly speciﬁc and
effective EWS/ATF1 inhibitors. Thus, it will be of interest
to utilize such molecules to downregulate EWS/ATF1 and
observe the biological effect on CCS cells.
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